Tiziana Expands Phase 2 of Foralumab at Weill Cornell Multiple Sclerosis Center

Tiziana Life Sciences (NASDAQ: TLSA) has expanded its Phase 2 clinical trial of intranasal foralumab by initiating patient dosing at Weill Cornell Multiple Sclerosis Center, marking the fifth site in their study. The trial evaluates foralumab, a first-in-class fully human anti-CD3 monoclonal antibody, in patients with non-active Secondary Progressive Multiple Sclerosis (na-SPMS). This site joins existing locations at Yale University, Johns Hopkins University, Brigham and Women's Hospital, and the University of Massachusetts. The study includes a six-month open-label extension phase following the blinded phase, allowing all participants to receive foralumab. The treatment's innovative intranasal delivery method aims to engage regulatory T cells and promote immune tolerance while minimizing systemic immune suppression.

https://www.stocktitan.net/news/TLSA/tiziana-life-sciences-expands-phase-2-clinical-trial-of-intranasal-rdtcraisie5v.html